Monday, March 12, 2012

HemaQuest Pharmaceuticals Taps Into $13M More

HemaQuest Pharmaceuticals, which is developing small molecule therapeutics for treating hemoglobain disorders such as sickle cell disease, said today that it has raised $13M in a Series B extension financing. The firm, which has its research operations in Seattle, said the funding came from Aberdare Ventures, De Novo Ventures, Forward Ventures, Latterell Venture Partners and Lilly Ventures, all existing investors. The new funds will go towards a Phase 2b clinical study to apply its compound to patients with sickle cell disease. HemaQuest's technology was originally developed at the Boston University School of Medicine, and its headquarters are in San Diego, California. More information »